Antila Bioscience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -36.66%
- Profit Growth -20.81%
- Ebitda -18.03%
- Net Worth 54.74%
- Total Assets -16.03%
About Antila Bioscience
Antila Bioscience Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 August 2013 and has a history of 11 years and six months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Shah, Jasmine Shah, Jignesh Sanghavi, and One other member serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233GJ2013PTC076354
-
Company No.
076354
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Aug 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Antila Bioscience?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaybhai Prajapati
|
Director | 05-Dec-2013 | Current |
|
Sanjay Shah
|
Director | 08-Aug-2013 | Current |
|
Jasmine Shah
|
Additional Director | 13-Dec-2016 | Current |
Jignesh Sanghavi
|
Director | 05-Dec-2013 | Current |
Financial Performance of Antila Bioscience.
Antila Bioscience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 36.66% decrease. The company also saw a substantial fall in profitability, with a 20.81% decrease in profit. The company's net worth Soared by an impressive increase of 54.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Antila Bioscience?
In 2022, Antila Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Espee Pharma Chem Private LimitedSanjay Shah is a mutual person
-
Antila Lifesciences Private LimitedSanjay Shah is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Antila Bioscience?
Unlock and access historical data on people associated with Antila Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Antila Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Antila Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
